September 2026 Japanese M&A Market Trends and GIP Advisory Track Record."In this webinar, we will explain the trends and notable deals in the Japanese M&A market for the July-September 2026 period, as ...

Spread the love“`html If you’ve been following the news, or just scrolling through social media, you’ve probably noticed a ...

Viking Therapeutics Inc VKTX shares are popping Thursday. The obesity drug developer reported third-quarter results that ...

Eli Lilly’s latest weight loss drug candidate, retatrutide, is already being talked about as a potential game changer in ...

Eli Lilly’s next generation weight loss drug, known as retatrutide, was shown to provide more than double the weight loss of ...

Eli Lilly's new experimental drug showed promising results in a head-to-head clinical trial, with more weight loss and ...

Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults ...

An experimental weight-loss drug from Eli Lilly led to more than twice the average weight loss of Ozempic in a clinical trial ...

OpenAI’s president, Greg Brockman, recently suggested that its advanced model, known as GPT-6 Astra, could mark the arrival ...

In the first head-to-head trial of Ozempic versus Eli Lilly's new "King Kong" drug retatrutide, the next-generation drug led ...

Eli Lilly's next generation weight loss drug, known as retatrutide, was shown to provide more than double the weight loss of ...

Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% ...